98 related articles for article (PubMed ID: 3461888)
1. Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Elisson O
Cancer Chemother Pharmacol; 1986; 17(3):296-7. PubMed ID: 3461888
[No Abstract] [Full Text] [Related]
2. Assessment of ventricular function by radionuclide angiography in patients receiving 4'-epidoxorubicin and mitoxantrone.
Vorobiof DA; Iturralde M; Falkson G
Cancer Chemother Pharmacol; 1985; 15(3):253-7. PubMed ID: 3863718
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of left ventricular function using radionuclide scans in patients receiving mitoxantrone.
Aapro MS; Alberts DS; Woolfenden JM; Mackel C
Invest New Drugs; 1983; 1(4):341-7. PubMed ID: 6678882
[TBL] [Abstract][Full Text] [Related]
4. Comment on mitoxantrone.
DuKart G; Iatropoulos MJ; Yacobi A
Drug Intell Clin Pharm; 1985 Mar; 19(3):216-8. PubMed ID: 3979268
[No Abstract] [Full Text] [Related]
5. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults.
Avilés A; Arévila N; Díaz Maqueo JC; Gómez T; García R; Nambo MJ
Leuk Lymphoma; 1993 Oct; 11(3-4):275-9. PubMed ID: 8260898
[TBL] [Abstract][Full Text] [Related]
6. [Recent contributions of chemotherapy to the treatment of breast cancer].
Focan C
Rev Med Liege; 1986 Mar; 41(5):158-64. PubMed ID: 3457413
[No Abstract] [Full Text] [Related]
7. Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.
Avilés A; Neri N; Nambo JM; Huerta-Guzman J; Talavera A; Cleto S
Leuk Lymphoma; 2005 Jul; 46(7):1023-8. PubMed ID: 16019553
[TBL] [Abstract][Full Text] [Related]
8. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of ventricular function in patients treated with mitoxantrone and 4'-epidoxorubicin].
Avilés A; Díaz-Maqueo JC; Arévila-Ceballos N; García Fernández R; López-Vancell D; Torras V
Arch Inst Cardiol Mex; 1989; 59(6):615-8. PubMed ID: 2624510
[TBL] [Abstract][Full Text] [Related]
10. Early and delayed clinical cardiotoxicity of doxorubicin.
Buzdar AU; Marcus C; Smith TL; Blumenschein GR
Cancer; 1985 Jun; 55(12):2761-5. PubMed ID: 3922612
[TBL] [Abstract][Full Text] [Related]
11. Radionuclide angiographic monitoring in patients treated with potentially cardiotoxic cytostatic drugs.
Vorobiof DA; Falkson G; Iturralde MP
S Afr Med J; 1988 Sep; 74(5):213-6. PubMed ID: 3166211
[TBL] [Abstract][Full Text] [Related]
12. A comparison of mitoxantrone and doxorubicin in breast cancer.
Neidhart JA; Gochnour D; Roach R; Hoth D; Young D
J Clin Oncol; 1986 May; 4(5):672-7. PubMed ID: 3517241
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
14. Myocyte cell damage after administration of doxorubicin or mitoxantrone in breast cancer patients assessed by indium 111 antimyosin monoclonal antibody studies.
Estorch M; Carrió I; Martínez-Duncker D; Berná L; Torres G; Alonso C; Ojeda B
J Clin Oncol; 1993 Jul; 11(7):1264-8. PubMed ID: 8315423
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
16. High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial.
Leiby JM; Unverfurth DV; Neidhart JA
Cancer Treat Rep; 1986 Jul; 70(7):899-901. PubMed ID: 3719583
[TBL] [Abstract][Full Text] [Related]
17. Cardiac evaluation of mitoxantrone.
Unverferth DV; Unverferth BJ; Balcerzak SP; Bashore TA; Neidhart JA
Cancer Treat Rep; 1983 Apr; 67(4):343-50. PubMed ID: 6850653
[TBL] [Abstract][Full Text] [Related]
18. [Epirubicin: an anthracycline of minor cardiotoxicity].
Rivero O; Mordeglia F
Medicina (B Aires); 1987; 47(3):320-1. PubMed ID: 3481643
[No Abstract] [Full Text] [Related]
19. Phase I trial of mitoxantrone in children.
Ungerleider RS; Pratt CB; Vietti TJ; Holcenberg JS; Kamen BA; Glaubiger DL; Cohen LF
Cancer Treat Rep; 1985 Apr; 69(4):403-7. PubMed ID: 3857968
[TBL] [Abstract][Full Text] [Related]
20. Effect of anthracyclines and mitoxantrone on oxygen uptake and ATP intracellular concentration in rat heart slices.
Neri B; Cini-Neri G; D'Alterio M
Biochem Biophys Res Commun; 1984 Dec; 125(3):954-60. PubMed ID: 6596102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
